Spectral AI, Inc. (MDAI) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics using its DeepView™ System for burn wound assessment. The company is currently in a pre-commercialization phase, generating revenue primarily through government research and development contracts, specifically with the Biomedical Advanced Research and Development Authority (BARDA) and the Medical Technology Enterprise Consortium (MTEC). The company filed a De Novo application with the FDA in June 2025 for its DeepView AI – Burn software.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Sept 30, 2025 Balance Sheet |
|---|---|---|---|
| Revenue | $3,792 | $15,564 | - |
| Gross Profit | $1,621 | $7,079 | - |
| Gross Margin | 42.7% | 45.5% | - |
| Operating Loss | $(3,341) | $(6,360) | - |
| Net Loss | $(3,552) | $(8,623) | - |
| Cash and Cash Equivalents | - | - | $10,495 |
| Total Debt (Notes Payable) | - | - | $7,795 |
| Warrant Liabilities | - | - | $8,586 |
| Accumulated Deficit | - | - | $(56,852) |
Note: Total Debt includes $1,214 current and $6,581 long-term notes payable. Warrant liabilities are classified as liabilities due to specific terms.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 53.6% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 29.2% year-to-date. This reduction reflects the winding down of specific research phases as the company approached its FDA De Novo submission.
- Increased Operating Loss: Operating loss widened significantly to $3.3 million for the quarter compared to $0.9 million in the prior year quarter, driven by sustained General and Administrative (G&A) expenses despite lower revenue.
- Debt Structure: The company secured an $8.5 million initial drawdown under a new $15.0 million credit facility with Avenue Capital Group in March 2025. Conversely, the company settled its Yorkville Convertible Notes during the period.
- Warrant Liability Volatility: The fair value of warrant liabilities increased to $8.6 million from $6.5 million at year-end 2024, contributing to non-cash expenses in the income statement.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management believes current cash resources ($10.5 million), combined with the Avenue Financing and existing government contracts, are sufficient to fund operations for at least one year. The company anticipates initial commercial sales in the UK in 2025 following UKCA authorization, pending FDA clearance for the US market.
Subsequent Events: In October 2025, the company completed a securities purchase agreement raising approximately $7.6 million through the sale of common stock and warrants.
Risks and Contingencies:
- Internal Control Weaknesses: The company identified two material weaknesses in internal controls over financial reporting: one related to the percentage-of-completion revenue recognition method and another regarding the financial statement close process. Remediation efforts are underway.
- Customer Concentration: A single U.S. government agency (BARDA) accounted for 85% of revenue in Q3 2025 and 92% for the nine-month period.
- Regulatory Dependence: Future commercial success is contingent upon FDA clearance of the DeepView System.
Investor Verification Checklist
- FDA Status: Verify the current status of the De Novo application filed in June 2025 and any updates on the UKCA commercial rollout.
- Internal Controls: Review the progress of remediation for the identified material weaknesses in revenue recognition and financial close processes.
- Debt Covenants: Examine the specific milestones required to unlock the second tranche ($6.5 million) of the Avenue Financing, specifically the requirement for a $7.0 million equity raise.
- Warrant Liability Impact: Assess the sensitivity of the $8.6 million warrant liability to stock price fluctuations and its impact on future net loss volatility.
- Government Contract Renewals: Confirm the timeline and likelihood of exercising options under the BARDA contract to sustain revenue post-2025.